CDMO News
OXB completes full acquisition of remaining stakes in US subsidiary
OXB, a global cell and gene therapy CDMO, has announced the acquisition of the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio. This move brings the company’s ownership of the US operation to 100%, as
24 June 2025